Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens

Journal of Laboratory and Clinical Medicine

Volumn 130, Issue 5, 1997, Pages 540-543

  Glueck, Charles J ^a   Mcmahon, Robert E ^b   Bouquot, Jerry E ^b   Triplett, Douglas ^b   Gruppo, Ralph ^b   Wang, Ping ^b  

^a JEWISH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031281384     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(97)90132-3     Document Type: Article

References (23)

1. Boettcher WG, Bonfiglio H, Hamilton HH, Sheets RF, Smith K. Non-traumatic osteonecrosis of the femoral head. Part 1. Relation of altered hemostasis to etiology. J Bone Joint Surg Am 1970;52:312-21.
2. Glueck CJ, Glueck HI, Welch M, et al. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor. Thromb Haemost 1994;71:195-8.
3. Glueck CJ, Freiberg R, Glueck HI, et al. Hypofibrinolysis: a common, major cause of osteonecrosis. Am J Hematol 1994; 45:156-66.
4. Glueck CJ, Freiberg R, Glueck HI, et al. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high Lp(a), and therapy with Stanozolol. Am J Hematol 1995;48:213-20.
5. Glueck CJ, Freiberg R, Tracy T, Stroop D, Wang P. Thrombophilia, hypofibrinolysis, and osteonecrosis. Clin Orthop 1997;334:43-56.
6. Glueck CJ, McMahon RE, Bouquot J, et al. Pathophysiology of osteonecrosis of the jaw: thrombophilia and hypofibrinolysis. Oral Surg Oral Med Oral Pathol 1996;81: 557-66.
7. Gruppo R, Glueck CJ, McMahon RE, et al. Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis: pathophysiology of osteonecrosis of the jaw. J Lab Clin Med 1996;127: 481-8.
8. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332: 912-7.
9. Glueck CJ, Brandt G, Gruppo R, et al. Resistance to activated protein C and Legg-Perthes disease. Clin Orthop 1997; 338:139-52.
10. Glueck CJ, Freiberg R, Gruppo R, Crawford A. Thrombophilia and hypofibrinolysis: pathogenetic etiologies of osteonecrosis [abstract]. J Invest Med 1997;45:254A.
11. Dahlback B. Physiological anticoagulation: resistance to activated protein C and venous thromboembolism. J Clin Invest 1994;94:923-7.
12. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
13. Jenny RJ, Pittman DD, Toole JJ, et al. Complete DNA and derived amino acid sequence of human factor V. Proc Nat Acad Sci U S A 1987;84:4846-50.
14. Koeleman PC, Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 1994;84: 1031-5.
15. Lindblom B, Holmlund G. Rapid DNA purification for restriction fragment length polymorphism analysis. Gene Anal Technol 1988;5:97-101.
16. Glueck CJ, Freiberg R, Gruppo R, et al. Thrombophilia and hypofibrinolysis: reversible pathogenetic etiologies of osteonecrosis in adults and children (Legg-Perthes disease). AOA International Symposium on osteonecrosis. In press.
17. Hirsch DR, Mikkola KM, Marks PW, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996;131:1145-8.
18. Rintelen C, Mannhalter C, Ireland H, et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996;93:487-90.
19. Bokarewa MI, Falk G, Sten-Linder M, Egberg N, Blomback M, Bremme K. Thrombotic risk factors and oral contraception. J Lab Clin Med 1995;126:294-8.
20. Heligren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173:210-3.
21. Bauersachs R, Lindhoff-Last E, Erhly AM, Kuhl H. Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives. Zentralbl Gynakol 1996;118:262-70.
22. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA 1997;1305-7.
23. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89: 2817-21.